Floatz logo

177lu-ctr-fapi

Adenocarcinoma of the Stomach

Xijing HospitalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

64 Active assets in the Adenocarcinoma of the Stomach cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Boehringer Ingelheim
Phase 3BB
TRASTUZUMAB
Boehringer Ingelheim
Phase 2BB
Capecitabine
Shanghai Zhongshan Hospital
Phase 3BB
Eloxatin
Shanghai Zhongshan Hospital
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 3BB

View all 50 →

Same molecule, other indications

177lu-ctr-fapi is also rated in:

metastatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
pancreatic neoplasmDormant
C
Indicative ·
33 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →